RxDoctor Payments Data

Mohinder Partap, MD

Psychiatry · Saint Louis, MONPI 1235137035

Payments from drug & device makers

$11,922in general payments, 2019–2025

Across 712 payments — averaging $16.74 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Alkermes, Inc.$1K
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$1K
  • Neurocrine Biosciences, Inc.$1K
  • Vanda Pharmaceuticals Inc.$818
  • Sunovion Pharmaceuticals Inc.$771
  • plus $5K from 36 others

What the payments were for

  • Food & beverage$11,898100%
  • Education$250%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$11,922 in reported general payments places this provider in the 90th percentile of 680 psychiatry providers in Missouri.

See all psychiatry providers in Missouri

Medicare billing

Part B allowed, 2024
$24,761
Medicare patients
71
Services billed
233

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
IngrezzaValbenazine Tosylate13$108,737
Aripiprazole155$14,943
Lurasidone Hcl36$10,018
Ziprasidone Hcl79$8,495
Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine149$4,964
Clozapine48$4,646
Paliperidone ErPaliperidone34$4,082
Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl57$2,984
Olanzapine101$2,672
Doxepin Hcl11$2,463
ZubsolvBuprenorphine Hcl/Naloxone Hcl11$2,431
Perphenazine22$2,315
Venlafaxine Hcl ErVenlafaxine Hcl59$2,180
Methylphenidate ErMethylphenidate Hcl38$1,908
Quetiapine Fumarate134$1,789

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Neurocrine Biosciences, Inc.Ingrezza$1,369$108,73713 claims
Orexo US, Inc.Zubsolv$176$2,43111 claims
Teva Pharmaceuticals USA, Inc.Loxapine$359$53311 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 680 psychiatry providers in Missouri.

Other psychiatry in Saint Louis

See the full list for Missouri

Where these figures come from

Is this you, or does something look wrong? →